RxDoctor Payments Data

Ashley Rice, DO

Dermatology · Wilmington, NCNPI 1932649324

Payments from drug & device makers

$5,501in general payments, 2019–2025

Across 230 payments — averaging $23.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Regeneron Healthcare Solutions, Inc.$508
  • Novartis$413
  • UCB, Inc.$362
  • Pfizer$359
  • Sun Pharmaceutical Industries Inc.$353
  • plus $2K from 16 others

What the payments were for

  • Food & beverage$5,486100%
  • Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,501 in reported general payments places this provider in the 65th percentile of 475 dermatology providers in North Carolina.

See all dermatology providers in North Carolina

Medicare billing

Part B allowed, 2024
$374,570
Medicare patients
1,075
Services billed
5,101

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab23$109,496
OtezlaApremilast11$51,197
Fluorouracil93$5,624
Ketoconazole285$4,779
Tacrolimus38$3,531
Calcipotriene23$3,515
Metronidazole55$3,411
Clobetasol Propionate69$3,004
Triamcinolone Acetonide154$1,344
Clindamycin Phosphate28$1,064
Mupirocin169$1,048
Ciclopirox35$926
Doxycycline Hyclate105$803
Fluocinonide14$622
Gentamicin Sulfate13$451

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$22$51,19711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 475 dermatology providers in North Carolina.

Other dermatology in Wilmington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →